Skip to main content
. 2017 May 24;8(31):51608–51620. doi: 10.18632/oncotarget.18209

Table 4. Response rate of patients with different MB4 breakpoints treated with bortezomib-based induction therapy.

Breakpoint ORR PR VGPR CR SD PD ≥VGPR SD+PD
MB4-1 (n=19) 100% (19/19) 15.8% (3/19) 47.4% (9/19) 36.8% (7/19) 0 (0/19) 0 (0/19) 84.2% (16/19) 0 (0/19)
MB4-2/MB4-3 (n=16) 75% (12/16) 18.8% (3/16) 37.5% (6/16) 18.8% (3/16) 6.3% (1/16) 18.8% (3/16) 56.3% (9/16) 25% (4/16)
P value 0.035 1 0.734 0.285 0.457 0.086 0.132 0.035